DaVita’s Analysts Lift Next-Year Earnings Estimates 9.8%, P/E 10.65 Well Below S&P
DaVita Inc. carries a Zacks Rank #1 with analysts boosting its next-year earnings estimates by 9.8% over the past 60 days. The kidney dialysis provider trades at a P/E of 10.65 versus the S&P’s 22.34 and holds a Value Score of A.
1. Zacks Rank and Earnings Revision
DaVita Inc. holds a top-tier Zacks Rank #1 designation as analysts have increased its next-year earnings forecast by 9.8% over the past 60 days, reflecting improved outlook in its core kidney dialysis operations.
2. Valuation Relative to Market
The company’s trailing P/E ratio of 10.65 is substantially below the S&P 500 average of 22.34, underscoring potential undervaluation given its earnings growth trajectory.
3. Value Score Assessment
DaVita has earned a Value Score of A, highlighting strong value characteristics driven by low valuation multiples and upward earnings revisions.
4. Implications for Investors
The combination of rising earnings estimates and below-market P/E may attract value-oriented investors seeking growth in healthcare services, though potential volatility in reimbursement rates warrants monitoring.